239 related articles for article (PubMed ID: 29669721)
21. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
22. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
23. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
Li B; VanRoey MJ; Jooss K
Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
26. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Curran MA; Allison JP
Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
28. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
[TBL] [Abstract][Full Text] [Related]
30. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
[TBL] [Abstract][Full Text] [Related]
32. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
34. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.
Jinushi M; Nakazaki Y; Dougan M; Carrasco DR; Mihm M; Dranoff G
J Clin Invest; 2007 Jul; 117(7):1902-13. PubMed ID: 17557120
[TBL] [Abstract][Full Text] [Related]
35. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
38. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
Zhu J; Liu JQ; Shi M; Cheng X; Ding M; Zhang JC; Davis JP; Varikuti S; Satoskar AR; Lu L; Pan X; Zheng P; Liu Y; Bai XF
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618655
[TBL] [Abstract][Full Text] [Related]
39. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
40. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
